{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:11:51Z","timestamp":1786990311558,"version":"build-2736575974"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,18]],"date-time":"2024-02-18T00:00:00Z","timestamp":1708214400000},"content-version":"am","delay-in-days":354,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1 TR003096"],"award-info":[{"award-number":["UL1 TR003096"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.ijantimicag.2023.106735","type":"journal-article","created":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T12:19:34Z","timestamp":1674217174000},"page":"106735","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Outcomes of Daptomycin Plus Ceftaroline Versus Alternative Therapy for Persistent Methicillin-resistant Staphylococcus aureus (MRSA) Bacteraemia"],"prefix":"10.1016","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8103-3554","authenticated-orcid":false,"given":"Darshan","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew L.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3910-9946","authenticated-orcid":false,"given":"Seth","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Oster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Stripling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ijantimicag.2023.106735_bib0001","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1093\/cid\/ciu583","article-title":"Avoiding the perfect storm: the biologic and clinical case for reevaluating the 7-day expectation for methicillin-resistant Staphylococcus aureus bacteremia before switching therapy","volume":"59","author":"Kullar","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106735_bib0002","first-page":"ciac364","article-title":"Persistent MRSA bacteremia: resetting the clock for optimal management","author":"Holland","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106735_bib0003","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1086\/598189","article-title":"Staphylococcus aureus bacteremia: epidemiology, pathophysiology, and management strategies","volume":"48","author":"Naber","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106735_bib0004","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/jac\/dkv368","article-title":"When sepsis persists: a review of MRSA bacteremia salvage therapy","volume":"71","author":"Kullar","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106735_bib0005","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1001\/archinte.167.17.1861","article-title":"Persistent Staphylococcus aureus bacteremia: an analysis of risk factors and outcomes","volume":"167","author":"Hawkins","year":"2007","journal-title":"Arch Intern Med"},{"issue":"4","key":"10.1016\/j.ijantimicag.2023.106735_bib0006","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/cid\/ciz257","article-title":"Defining the breakpoint duration of Staphylococcus aureus bacteremia predictive of poor outcomes","volume":"70","author":"Minejima","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.ijantimicag.2023.106735_bib0007","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S1473-3099(20)30447-3","article-title":"Defining persistent Staphylococcus aureus bacteremia: secondary analysis of a prospective cohort study","volume":"20","author":"Kuehl","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106735_bib0008","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.ijantimicag.2023.106735_bib0009","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/cid\/civ808","article-title":"Combination of vancomycin and beta-lactam therapy for methicillin-resistant Staphylococcus aureus bacteremia: a pilot multicenter randomized controlled trial","volume":"62","author":"Davis","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.ijantimicag.2023.106735_bib0010","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1001\/jama.2020.0103","article-title":"Effect of vancomycin or daptomycin with or without an anti-staphylococcal \u03b2-lactam on mortality, bacteremia relapse, or treatment failure in patients with MRSA bacteremia","volume":"323","author":"Tong","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2023.106735_bib0011","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.clinthera.2014.09.005","article-title":"Daptomycin in combination with other antibiotics for the treatment of complication methicillin-resistant Staphylococcus aureus bacteremia","volume":"36","author":"Dhand","year":"2014","journal-title":"Clin Ther"},{"key":"10.1016\/j.ijantimicag.2023.106735_bib0012","first-page":"201","article-title":"Daptomycin plus \u00df-lactam combination therapy for methicillin-resistant Staphylococcus aureus bloodstream infections: a retrospective, comparative cohort study","author":"Jorgensen","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106735_bib0013","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1128\/AAC.01204-13","article-title":"\u00df-lactams enhance vancomycin activity against methicillin-resistant Staphylococcus aureus bacteremia compared to vancomycin alone","volume":"58","author":"Dilworth","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106735_bib0014","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s40121-020-00292-8","article-title":"Monotherapy with vancomycin or daptomycin versus combination therapy with \u00df-lactams in the treatment of methicillin-resistant Staphylococcus aureus bloodstream infections: a retrospective cohort analysis","volume":"9","author":"Alosaimy","year":"2020","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.ijantimicag.2023.106735_bib0015","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1128\/AAC.02371-13","article-title":"Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy","volume":"58","author":"Casapao","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106735_bib0016","doi-asserted-by":"crossref","first-page":"e02015","DOI":"10.1128\/AAC.02015-16","article-title":"Multicenter observational study of ceftaroline fosamil for methicillin-resistant Staphylococcus aureus bloodstream infections","volume":"61","author":"Zasowski","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.ijantimicag.2023.106735_bib0017","doi-asserted-by":"crossref","first-page":"ofab606","DOI":"10.1093\/ofid\/ofab606","article-title":"Multicenter cohort study of ceftaroline versus daptomycin for treatment of methicillin-resistant Staphylococcus aureus bloodstream infection","volume":"9","author":"Zasowski","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106735_bib0018","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1128\/AAC.01586-12","article-title":"Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic\/pharmacodynamic model","volume":"57","author":"Werth","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106735_bib0019","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/jac\/dku378","article-title":"The combination of ceftaroline plus daptomycin allows for therapeutic de-escalation and daptomycin sparing against MRSA","volume":"70","author":"Barber","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106735_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.02483-18","article-title":"Clinical data on daptomycin plus ceftaroline versus standard of care monotherapy in the treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"63","author":"Geriak","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.ijantimicag.2023.106735_bib0021","doi-asserted-by":"crossref","first-page":"ofz538","DOI":"10.1093\/ofid\/ofz538","article-title":"Multicenter cohort of patients with methicillin resistant Staphylococcus aureus bacteremia receiving daptomycin plus ceftaroline compared to with other MRSA treatments","volume":"7","author":"McCreary","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106735_bib0022","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.clinthera.2014.05.061","article-title":"Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline","volume":"36","author":"Sakoulas","year":"2014","journal-title":"Clin Ther"},{"issue":"7","key":"10.1016\/j.ijantimicag.2023.106735_bib0023","doi-asserted-by":"crossref","first-page":"ofab327","DOI":"10.1093\/ofid\/ofab327","article-title":"Clinical outcomes with definitive treatment of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia with retained daptomycin and ceftaroline combination therapy versus de-escalation to monotherapy with vancomycin, daptomycin, or ceftaroline","volume":"8","author":"Nichols","year":"2021","journal-title":"Open Forum Infect Dis"},{"issue":"12","key":"10.1016\/j.ijantimicag.2023.106735_bib0024","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1093\/cid\/ciab452","article-title":"Current paradigms of combination therapy in methicillin-resistant Staphylococcus aureus (MRSA) bacteremia: Does it work, which combination, and for which patients?","volume":"73","author":"Rose","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.ijantimicag.2023.106735_bib0025","first-page":"88","article-title":"Epidemic Clostridium difficile-associated diarrhea: role of second- and third-generation cephalosporins","volume":"15","author":"Nelson","year":"1994","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"4","key":"10.1016\/j.ijantimicag.2023.106735_bib0026","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1365-2710.2007.00836.x","article-title":"Influence of third-generation cephalosporin utilization on the occurrence of ESBL-positive Klebsiella pneumoniae strains","volume":"32","author":"Urbanek","year":"2007","journal-title":"J Clin Pharm Ther"},{"issue":"7","key":"10.1016\/j.ijantimicag.2023.106735_bib0027","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1086\/666331","article-title":"Association between vancomycin-resistant enterococci bacteremia and ceftriaxone usage","volume":"33","author":"McKinnell","year":"2012","journal-title":"Infect Control Hosp Epidemiol"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857923000237?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857923000237?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:45:04Z","timestamp":1760377504000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857923000237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0924857923000237"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106735","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of Daptomycin Plus Ceftaroline Versus Alternative Therapy for Persistent Methicillin-resistant Staphylococcus aureus (MRSA) Bacteraemia","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106735","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106735"}}